Navigating the 'Wild West' of Brain Health Startup Funding

News and Insights

Navigating the "Wild West" of Brain Health Startup Funding

June 29, 2026

Peel back the promise and excitement around the rapid acceleration of brain health innovations and a stark reality emerges. The convergence of pioneering discoveries in cognitive performance and decline, AI, and promising neuro technologies have provided a much-needed boost for new approaches to improving human longevity. But the demand for funding breakthrough initiatives dwarfs the supply of available venture capital.

The boom in brain health is different from other moments. A great marketing plan and glitzy tech aren't enough to attract investors right now. To navigate the "Wild West" of brain health entrepreneurship, a delicate balance of strong domain knowledge, rigorous real-world validation, and a proactive approach to commercialization.

To help entrepreneurs map out better strategies for successfully securing new funding, FINN convened two leading early-stage investors in brain health and one market-scale expert who has advised several hundred start-ups for a conversation on key approaches entrepreneurs should take when preparing their go-to-market plans.

Hosted in partnership with mHealth Israel, the panel event at FINN's New York City headquarters attracted more than 60 founders, industry experts and potential entrepreneurs on June 22, and helped to decode the increasingly complex landscape of early-stage funding for brain health, mental health, and neurotechnology startups. The dynamic conversation and engagement with the audience revealed three top-line points:

1. Market Trends: Deepening Domain Knowledge and Segmentation

As artificial intelligence increasingly becomes the baseline for digital health applications, staying ahead of the curve means having specialized clinical insights.

Dr. Gal Noyman Veksler, PhD, a partner at LionBird, emphasized that generic applications are making way for highly technical teams. Investors are looking more critically at startups that bring a comprehensive group of both clinical and business domain experts to the table when they make funding decisions: "It's about having a team with specific domain knowledge to create the most meaningful AI and business advantage from the very beginning" she said.

The market also is shifting away from generic direct-to-consumer (B2C) chat apps aimed at replacing therapists, evolving instead into highly targeted, population-specific software or hardware configurations. Dr. Maria Blekher, PhD, a behavioral scientist by training and co-founder and managing partner at Serendipity Impact VC, observed this transition toward niche specialization: "There is a saying that if it's for everyone, it's for no one. So you do need to be clear about your audience segmentation from the start."

2. The Customer is King: Validation Over Assumptions

A critical mistake many founders make is relying too heavily on logical assumptions rather than hard data. In healthcare delivery, your absolute biggest competitor is the status quo. If groundbreaking technology disrupts an established workflow without integrating smoothly, it faces severe resistance. Dr. Blekher strictly advised founders to conduct practical, hands-on customer discovery: "Less assumptions, more real-world data and validation. Unless you've seen it firsthand, sometimes the thing that sounds the most logical is not what works in real life."

This sentiment was mirrored by Esther Howard, founder of Bezyl, a company dedicated to scaling brain health innovations. "Validation doesn't just mean efficacy and safety. It also means usability. If you don't have usability in your validation, then they're really going to be upset at you, she said."

3. Commercialization: Designing for Reimbursement Early

One of the defining realities of the U.S. healthcare market is its structural fragmentation and notoriously long sales cycles. Esther Howard noted that it can easily take two years from an initial customer meeting to securing a corporate or healthcare contract. To survive this endurance test, founders must think about their reimbursement strategy long before launching their product. "Reimbursement must be designed before launch. Just because it works doesn't mean CMS and insurance companies are going to pay for it, she said."

For early-stage startups seeking faster initial traction, Howard highlighted alternative pathways:

"If you want to get quick traction and get revenue within six months, for example, you can do that in a nonprofit organization that really needs your solution."

The Final Say

Ultimately, the panelists agreed that while innovation captures market attention, it is strategic partnerships, clinical safety guardrails, and persistent relationship-building that drive true, scalable adoption. For founders in the brain health space, mapping out a clear runway and embracing real-world clinical environments are the ultimate keys to transforming the wilderness of the current brain health landscape into an ecosystem that benefits patients, entrepreneurs and health practitioners.

The full conversation is worth listening to in its entirety and can be found here.

Follow FINN Partners on LinkedIn and tune in to future thought-provoking sessions on brain health issues.

• Share this page on Facebook
• Share this page on LinkedIn
• Share this page on Twitter

• TAGS:

• Health Thought Leadership
• ,
• Global Health Impact
• ,
• Health

POSTED BY: Richard Hatzfeld